Highlights

  • Biome Australia shares rose 8.33% during morning trade on 27 May 2026.
  • The company commenced recruitment for its BMB18 clinical trial across Australia and Greece.
  • The study will involve 240 participants across two academic centres.
  • BMB18 is Biome’s first wholly proprietary probiotic strain.
  • Ethics approvals and site agreements are already in place at both centres.

Biome Australia Ltd (ASX:BIO) shares moved higher during the morning session on 27 May 2026, rising 8.33% to AUD 0.26 after the company announced the commencement of its international multi-centre clinical trial for BMB18, a proprietary probiotic strain being developed within its intellectual property portfolio.

The update appeared to attract investor attention as the company progresses from pre-clinical development toward human clinical evaluation for one of its internally developed probiotic candidates.

Although Biome Australia shares remain down approximately 39.53% over the past year, today’s gain follows a series of announcements related to the expansion of the company’s proprietary Research and Development pipeline.

Biome Australia develops and commercialises evidence-based probiotics and complementary medicines through its Activated Probiotics and Activated Therapeutics brands, focusing on products supported by clinical research and practitioner-led distribution channels.

International Multi-Centre Trial Begins Recruitment

Biome Australia confirmed that recruitment has commenced this week for the BMB18 clinical trial across two academic research centres: La Trobe University in Melbourne and Harokopio University of Athens in Greece.

The study was originally planned as a single-centre trial at La Trobe University but has now been expanded into an international multi-centre program.

According to the company, this marks the first time the Athens site addition has been disclosed publicly.

The expanded study design is intended to strengthen both the scientific credibility and recruitment capacity of the program through concurrent operation across two independent academic institutions.

Harokopio University of Athens will conduct the study under the Leadership of Professor George Moschonis, Professor of Human Nutrition at the university.

Biome noted that Harokopio University ranked second in Greece in the Times Higher Education World University Rankings 2026 and first in Greece for research quality.

The university’s Department of Nutrition and Dietetics is recognised for its clinical nutrition and dietetics research activity across Europe.

Trial Design Targets 240 Participants

The BMB18 study has been designed as a randomised, double-blind, placebo-controlled clinical trial involving 240 participants.

Participants will be allocated across three separate trial arms evaluating two dosage levels of BMB18 against placebo.

The study will assess daily dosages of 1×10⁹ CFU and 10×10⁹ CFU over a six-week intervention period, followed by a two-week post-treatment follow-up phase.

Biome stated that both academic centres are operating under a harmonised trial protocol with materially equivalent site agreements already executed.

The dose-response structure is expected to provide the first human clinical evidence for the BMB18 strain across two separate academic populations.

Management believes the multi-centre approach could strengthen the quality and interpretability of future clinical findings.

Recruitment Timeline Remains on Track

The company stated that recruitment commencement remains aligned with the Q4 FY26 timeline previously disclosed in April 2026.

Biome also confirmed that all required ethics approvals have been secured at both participating centres.

In addition, the clinical trial products have already been manufactured, released and delivered to both trial locations ahead of recruitment activities.

The company’s ability to commence recruitment within the originally guided timeframe appears to have been viewed favourably by investors, particularly given the additional complexity involved in expanding the study internationally.

Clinical-stage healthcare and biotechnology companies are often closely monitored for execution against trial timelines, ethics approvals and patient recruitment milestones, as delays in these areas can impact broader development schedules.

BMB18 Represents Key Intellectual Property Asset

BMB18, formally identified as Lactiplantibacillus plantarum DSM 35214, represents the first wholly proprietary strain within Biome Australia’s intellectual property pipeline.

The company stated that pre-clinical work has identified three mechanisms of action associated with the strain, including effects relating to intestinal barrier function, immunomodulation and antioxidant activity.

Biome has already filed a Patent application covering the strain and its potential applications, while a corresponding Budapest Treaty patent deposit process is currently underway through DSMZ.

The company noted that clinical trial outcomes cannot yet be predicted and that patent applications remain subject to examination processes.

Nevertheless, the commencement of human clinical evaluation represents an important step in the progression of the BMB18 development program.

Expansion Seen as Strategic Step for Proprietary Pipeline

Biome Australia Founder and Managing Director Blair Vega Norfolk described the expanded international trial design as a meaningful development for the company’s broader proprietary intellectual property strategy.

According to management, operating concurrently across two internationally recognised academic centres could improve the recruitment footprint and credibility of the trial.

The company believes this reflects ongoing maturation of its internal research and development platform as it moves beyond commercial probiotic distribution toward greater ownership of proprietary strains and clinical Assets.

The addition of an international research centre may also broaden the future applicability and recognition of the trial outcomes across multiple markets.

For emerging healthcare companies, development of proprietary intellectual property assets is often viewed as strategically important due to the potential for future licensing, commercial partnerships and differentiated product positioning.

Biome’s Broader Business Model

Biome Australia operates in the probiotics and complementary medicines sector, focusing on evidence-based products supported by scientific research.

Founded in 2018, the company develops, licenses, commercialises and markets live biotherapeutic products through practitioner-only distribution channels both in Australia and internationally.

Its flagship Activated Probiotics range includes products targeting several health categories, including gut health, low mood and sleep support, bone health, eczema, iron malabsorption and irritable bowel syndrome.

Biome works with research organisations and microbiome-focused development partners to support formulation development and clinical validation of its products.

The company has also focused heavily on educating healthcare professionals regarding the relationship between gut microbiota and broader systemic health outcomes.

This practitioner-led approach forms a key component of the company’s commercial strategy within the growing global probiotics and microbiome health market.

Clinical Research Continues Expanding in Probiotic Sector

The probiotics and microbiome research industry has continued attracting growing scientific and commercial attention over recent years, particularly as researchers explore links between gut health and broader physiological functions.

Biome’s latest trial announcement reflects this broader trend toward clinically supported probiotic formulations and strain-specific research.

Unlike general nutritional supplements, clinically studied probiotic strains often seek to establish evidence-based differentiation through controlled human trials.

The BMB18 study’s placebo-controlled and double-blind design aligns with research methodologies commonly used to assess efficacy and safety in emerging healthcare and nutritional products.

The inclusion of multiple dosage levels may also provide additional insights into potential dose-response relationships associated with the strain.

Investors Watching Progression of Proprietary Programs

Today’s market reaction suggests investors are closely monitoring Biome Australia’s efforts to strengthen its proprietary product pipeline and clinical research profile.

While the company remains relatively early in the clinical development process for BMB18, the commencement of recruitment across two international academic centres marks a notable operational milestone.

The expansion from a single-centre Australian study to an international multi-centre design may also improve visibility for the BMB18 program within the broader microbiome and probiotic research landscape.

Biome indicated that additional updates regarding the trial will be provided in accordance with ongoing disclosure obligations as the program progresses.